ESMO 2024: Treatment of uHCC - Episode 2

Treatment Decisions Based on BLCL Stage

, , , , ,

Panelists discuss current treatment options for unresectable hepatocellular carcinoma, including atezolizumab plus bevacizumab, durvalumab plus tremelimumab, and transarterial chemoembolization, along with the factors influencing treatment decisions.

EP. 1: Current Treatment Landscape – difference between unresectable (uHCC) and metastatic (mHCC)
Now Viewing
EP. 2: Treatment Decisions Based on BLCL Stage
EP. 3: Current Treatment in First Line – IO + TKI or IO + IO
EP. 4: Use of monotherapy (IO or TKI) or localized treatment in First Line
EP. 5: EMERALD-1 Study Results
EP. 6: Discussion and Summary
EP. 7: LEAP-012 Study Results
EP. 8: Discussion of LEAP-012 and EMERALD-1 Study Results and Appropriate Sequencing
EP. 9: ImBRAVE 050 Study Results and Discussion Around Who is a High-Risk Patient
EP. 10: Choosing Second-Line Therapies: Considering First Line Therapy Received
EP. 11: Discussion of CELESTIAL Trial and Second-Line Treatment in Japan
EP. 12: CELESTIAL Sub-Group Discussion
EP. 13: Discussion of RESORCE Trial
EP. 14: Real-World Treatment Data from the Phase 4 STELLAR Trial

Video content above is prompted by the following:

  • What are the current treatment options, and what factors drive your treatment decision?
    • Atezolizumab plus bevacizumab (ImBRAVE 150 – Kudo et al. Liver Cancer. 2022)
    • Durvalumab plus tremelimumab (HIMALAYA – Sangro et al. Ann Oncol. 2024)

Related Content:

ESMO 2024: Treatment of uHCC
Discussion of RESORCE Trial
Real-World Treatment Data from the Phase 4 STELLAR Trial
Discussion of CELESTIAL Trial and Second-Line Treatment in Japan